← All trials
NCT00295269
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 1, 1997
- Primary completion
- —
- Completion date
- Sep 1, 2005
- First posted
- —
- Last posted
- —
- Enrollment
- 200
- Arms / groups
- — / —
- Source
- AACT · pre-existing
Sponsors
- National Heart, Lung, and Blood Institute (NHLBI)Lead sponsor
- University of Colorado, DenverOverall official - principal investigator
- Duke UniversityOverall official - principal investigator
- University of WashingtonOverall official - principal investigator
- University of PennsylvaniaOverall official - principal investigator
- University of MarylandOverall official - principal investigator
- University of MichiganOverall official - principal investigator
- Vanderbilt UniversityOverall official - principal investigator
- Harvard UniversityOverall official - principal investigator
- Latter Day Saints HospitalOverall official - principal investigator
- University of RochesterOverall official - principal investigator
- University of California, BerkeleyOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.